Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In June 1906, President Theodore Roosevelt signed into law the Pure Food and Drug Act of 1906, also known as the "Wiley Act" after its chief advocate. The Act prohibited, under penalty of seizure of goods, the interstate transport of food that had been "adulterated". The act applied similar penalties to the interstate marketing of "adulterated" drugs, in which the "standard of strength, quality, or purity" of the active ingredient was not either stated clearly on the label or listed in the United States Pharmacopeia or the National Formulary. The responsibility for examining food and drugs for such "adulteration" or "misbranding" was given to Wiley's USDA Bureau of Chemistry. Wiley used these new regulatory powers to pursue an aggressive campaign against the manufacturers of foods with chemical additives, but the Chemistry Bureau's authority was soon checked by judicial decisions, which narrowly defined the bureau's powers and set high standards for proof of fraudulent intent. In 1927, the Bureau of Chemistry's regulatory powers were reorganized under a new USDA body, the Food, Drug, and Insecticide Administration. This name was shortened to the Food and Drug Administration (FDA) three years later. By the 1930s, muckraking journalists, consumer protection organizations, and federal regulators began mounting a campaign for stronger regulatory authority by publicizing a list of injurious products that had been ruled permissible under the 1906 law, including radioactive beverages, mascara that could cause blindness, and worthless "cures" for diabetes and tuberculosis.
The Golden Gate assembly protocol was defined by Engler et al. 2008 to define a DNA assembly method that would give a final construct without a scar sequence, while also lacking the original restriction sites. This allows the protein to be expressed without containing unwanted protein sequences which could negatively affect protein folding or expression. By using the BsaI restriction enzyme that produces a 4 base pair overhang, up to 240 unique, non-palindromic sequences can be used for assembly. Plasmid design and assembly In Golden Gate cloning, each DNA fragment to be assembled is placed in a plasmid, flanked by inward facing BsaI restriction sites containing the programmed overhang sequences. For each DNA fragment, the 3' overhang sequence is complementary to the 5' overhang of the next downstream DNA fragment. For the first fragment, the 5' overhang is complementary to the 5' overhang of the destination plasmid, while the 3' overhang of the final fragment is complementary to the 3' overhang of the destination plasmid. Such a design allows for all DNA fragments to be assembled in a one-pot reaction (where all reactants are mixed together), with all fragments arranged in the correct sequence. Successfully assembled constructs are selected by detecting the loss of function of a screening cassette that was originally in the destination plasmid. MoClo and Golden Braid The original Golden Gate Assembly only allows for a single construct to be made in the destination vector .
==== Insects and invertebrates ==== Most bats, especially in temperate areas, prey on insects. The diet of an insectivorous bat may span many species, including flies, mosquitos, beetles, moths, grasshoppers, crickets, termites, bees, wasps, mayflies and caddisflies. They will also eat other arthropods such as spiders, scorpions, centipedes, lobsters and shrimp. Large numbers of Mexican free-tailed bats (Tadarida brasiliensis) fly hundreds of metres above the ground in central Texas to feed on migrating moths. Species that hunt insects in flight, like the little brown bat (Myotis lucifugus) and the eastern red bat (Lasiurus borealis), may catch an insect in mid-air directly with the mouth or use their tail membranes or wings. The slow-moving brown long-eared bat (Plecotus auritus) plucks insects from vegetation, while many horseshoe bat species wait for them from their perches. Some bats may take the insect to their roost and eat it there. Arthropod-eating bats living at high latitudes have to consume prey with higher energetic value than tropical bats.
Concerns over average genital appearance or measurements are largely unavailable and make defining a successful outcome for such surgery difficult. A number of sex reassignment surgeries are available to transgender people. Although not all intersex conditions require surgical treatment, some choose genital surgery to correct atypical anatomical conditions.
== Composition == The substance is primarily composed of polysaccharides, including galactose, rhamnose, and α-glucuronic acid. It also contains dietary fiber, carbohydrates, proteins, and small amounts of vitamins. Despite marketing claims, peach gum does not contain collagen, which is exclusive to animal tissues.
Sources: en.wikipedia.org
Seaborg, a scientist at Lawrence Berkeley National Laboratory who had been involved in work to make such superheavy elements, had said in December 1997 that "one of his longest-lasting and most cherished dreams was to see one of these magic elements"; he was told of the synthesis of flerovium by his colleague Albert Ghiorso soon after its publication in 1999. Ghiorso later recalled:
and the Justice Department to investigate the contra-drug connection." Other journalists, including James Adams of The New York Times, were critical of Webb's work with his sources. Adams denounced Webb for his failure to contact the CIA and "cross check sources and allegations" and concluded, "For investigative reporters determined to uncover the truth, procedures like these are unacceptable." The series resulted in three federal investigations (by the CIA, the Department of Justice, and the House Intelligence Committee) into the claims of "Dark Alliance." The reports rejected his main claims but were critical of some CIA and law enforcement actions. The CIA report found no evidence that "any past or present employee of CIA, or anyone acting on behalf of CIA, had any direct or indirect dealing" with Ross, Blandón, or Meneses or that any of the other figures mentioned in "Dark Alliance" were ever employed by or associated with or contacted by the agency. The Department of Justice report stated that "We did not find that he [Blandón] had any ties to the CIA, that the CIA intervened in his case in any way, or that any connections to the Contras affected his treatment." The House Committee report examined the support that Meneses and Blandón gave to the local Contra organization in San Francisco and the Contras in general and concluded that it was "not sufficient to finance the organization" and did not consist of "millions," contrary to the claims of the "Dark Alliance" series.
== Legacy == In 1976, the National Park Service designated the Charles Richard Drew House in Arlington County, Virginia, as a National Historic Landmark in response to a nomination by the Afro-American Bicentennial Corporation. In 1981, the United States Postal Service issued a 35¢ postage stamp in its Great Americans series to honor Drew. In 2002, scholar Molefi Kete Asante listed Drew as one of the 100 Greatest African Americans.
=== Limitations to bioavailability === A recent study has shown Chlorambucil to be detoxified by human glutathione transferase Pi (GST P1-1), an enzyme that is often found over-expressed in cancer tissues. This is important since Chlorambucil, as an electrophile, is made less reactive by conjugation with glutathione, thereby making the drug less toxic to the cell.
Protein dimers arise from the interaction between two proteins which can interact further to form larger and more complex oligomers. For example, tubulin is formed by the dimerization of α-tubulin and β-tubulin and this dimer can then polymerize further to make microtubules. For symmetric proteins, the larger protein complex can be broken down into smaller identical protein subunits, which then dimerize to decrease the genetic code required to make the functional protein.
Sources: en.wikipedia.org
=== 1963–1998: Bob Rosenberg === In 1963, Rosenberg's son Bob became CEO of the company at age 25, and Dunkin' Donuts opened its hundredth location that year. Dunkin' Donuts was a subsidiary of Universal Food Systems at the time, a conglomerate of 10 small food-service businesses, and Dunkin' Donuts locations varied greatly in their menu options, with some selling full breakfasts and others serving only doughnuts and coffee. In the following years, the other businesses in the Universal Food Systems portfolio were sold or closed, and the company was renamed to Dunkin' Donuts. The menu and shop format was standardized, and various new menu items were introduced. In the early 1980s, counter service and ceramic coffee cups were replaced by self-service counters and paper cups. The chain went public in 1968 and was acquired by Baskin-Robbins owner Allied Lyons in 1990. Dunkin' Donuts expanded in the 1990s by buying out two rival chains: Mister Donut (which was founded by Bill Rosenberg's former partner Harry Winokur) and Dawn Donuts.
The Soviet Union placed great emphasis on science and technology. Lenin believed the USSR would never overtake the developed world if it remained as technologically backward as it was upon its founding. Soviet authorities proved their commitment to Lenin's belief by developing massive networks and research and development organizations. In the early 1960s, 40% of chemistry PhDs in the Soviet Union were attained by women, compared with only 5% in the United States. By 1989, Soviet scientists were among the world's best-trained specialists in several areas, such as energy physics, selected areas of medicine, mathematics, welding, space technology, and military technologies. However, due to rigid state planning and bureaucracy, the Soviets remained far behind the First World in chemistry, biology, and computer science. Under Stalin, the Soviet government persecuted geneticists in favour of Lysenkoism, a pseudoscience rejected by the scientific community in the Soviet Union and abroad but supported by Stalin's inner circles. Implemented in the USSR and China, it resulted in reduced crop yields and is widely believed to have contributed to the Great Chinese Famine. In the 1980s, the Soviet Union had more scientists and engineers relative to the world's population than any other major country, owing to strong levels of state support. Some of its most remarkable technological achievements, such as launching the world's first space satellite, were achieved through military research.
=== Parasites === Emus can suffer from both external and internal parasites, but under farmed conditions are more parasite-free than ostriches or rheas. External parasites include the louse Dahlemhornia asymmetrica and various other lice, ticks, mites and flies. Chicks sometimes suffer from intestinal tract infections caused by coccidian protozoa, and the nematode Trichostrongylus tenuis infects the emu as well as a wide range of other birds, causing haemorrhagic diarrhoea. Other nematodes are found in the trachea and bronchi; Syngamus trachea causing haemorrhagic tracheitis and Cyathostoma variegatum causing serious respiratory problems in juveniles.
=== "Cell-free fermentation" === Nevertheless it was known that living yeast cells were not a requirement for fermentation. In 1897 the German chemist and zymologist Eduard Buchner of Humboldt University of Berlin found that sugar was fermented even when there were no living yeast cells in the mixture, by an enzyme complex secreted by yeast that he termed zymase. In 1907 he received the Nobel Prize in Chemistry for his research and discovery of "cell-free fermentation". One year earlier in 1906 ethanol fermentation studies led to the early discovery of oxidized nicotinamide adenine dinucleotide (NAD+).
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.